Johnson & Johnson vs Legend Biotech Corporation — Stock Comparison
Johnson & Johnson (JNJ) and Legend Biotech Corporation (LEGN) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Johnson & Johnson narrowly edges Legend Biotech Corporation on Q·Score (7 vs 6.4 out of 10), led by Quality (9.3 vs 2.8) and Sentiment (7.4 vs 6.9). Legend Biotech Corporation scores higher on Valuation, reflecting stronger P/E and price-target positioning. Analyst consensus targets imply greater upside for LEGN (+174.4%) than for JNJ (+4.0%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
High-quality business with 26% return on equity and 21% profit margins.
⚠ earnings contracting 1% year-over-year.
Consensus analyst target of $48.48 is 174% above current price.
⚠ currently unprofitable (-7% margin).
Analyst Consensus
Fundamentals
Frequently Asked Questions
JNJ vs LEGN: which stock scores better overall?
Based on Q·Score, Johnson & Johnson (JNJ) scores 7/10 versus Legend Biotech Corporation (LEGN) at 6.4/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: JNJ or LEGN?
Legend Biotech Corporation (LEGN) scores higher on Growth (5.8/10 vs 5/10). Johnson & Johnson reports revenue growth (6.6% YoY) while Legend Biotech Corporation reports (51.9% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is JNJ or LEGN more attractively valued?
Legend Biotech Corporation (LEGN) scores higher on Valuation (9.1/10 vs 6.5/10). JNJ trades at 21.8× P/E versus LEGN at 16.8×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about JNJ vs LEGN?
There are 22 analysts covering JNJ with a consensus price target of $277.91, and 14 analysts covering LEGN with a consensus target of $48.48. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: JNJ or LEGN?
Johnson & Johnson (JNJ) scores higher on Quality (9.3/10 vs 2.8/10). Net profit margin: JNJ at 21.5%, LEGN at -7.2%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: JNJ or LEGN?
Legend Biotech Corporation (LEGN) scores higher on Financial Health (8.4/10 vs 6.5/10). Market beta: JNJ at 0.23, LEGN at 0.40. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of JNJ and LEGN?
Johnson & Johnson (JNJ) has a market capitalisation of $643.9B, while Legend Biotech Corporation (LEGN) has a market cap of $3.4B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do JNJ or LEGN pay dividends?
JNJ pays a dividend yield of 2.01%, while LEGN does not currently pay a dividend. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →